Transparency Market Research

Natural Killer Cell Lymphomas Market Analysis, Size, Share, Trends and Forecast 2019

Transparency Market Research Report Added "Natural Killer Cell Lymphomas Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" to its database.

 
Repost This

Albany, NY -- (SBWIRE) -- 07/08/2014 -- Lymphoma is a common blood cancer type which develops when lymphocytes multiply in an uncontrolled manner. There are two types of lymphomas- Hodgkin’s and non-Hodgkin’s lymphoma, out of which non-Hodgkin’s lymphoma is more common. Natural killer cell (NK) lymphoma is a type of non-Hodgkin’s lymphoma. There are three types of NK cell lymphomas namely, extranodal, nasal type and aggressive NK cell lymphoma. Extranodal lymphomas occur in organs other than lymph nodes, hence called as extranodal lymphomas. Nasal type of NK cell lymphomas usually affects nasal areas and paranasal sinuses. Aggressive form of the lymphoma is a very fast growing cancer, because of which prognosis is difficult to study. NK cell lymphomas are also shown to be associated with Epstein Barr Virus (EBV).

Browse the full report with request TOC at http://www.transparencymarketresearch.com/natural-killer-cell-lymphomas.html

Research and development activities has been impairedbecause of unpredictable prognosis and rare prevalence. Currently Cytoxan (cyclophosphamide), Procytox (cyclophosphamide), Adriamycin(doxorubicin), Oncovin(vincristine), Deltasone (prednisone) are widely used in chemotherapy. While radiation therapy is also practiced for treating the cancer. Various research institutes and corporates are also trying to discover new means to treat the cancer. These include Kirin Holdings Company, Mundipharma International Limited, Fred Hutchinson Cancer Research Center, Sun Yat-sen University, Seoul National University Hospital, University of Minnesota, Zhengzhou University, and M.D. Anderson Cancer Center. Study conducted by Zhengzhou University is currently under Phase IV trial which focuses in evaluation of gemcitabine, pegaspargase, cisplatin, and dexamethasone for chemotherapy.

Buy This Report with 10% Discount and Customize as per Your Requirement @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2361

A study published in Journal of Rare Diseases in 2013, have shown that NK cell lymphomas are common in Asia, Latin America and Central America as compared to North America and Europe. As the prevalence is higher in developing economies, cost of the treatment will be a major barrier for market growth. But a strong pipeline and rising incidences of cancer is expected to support the market in the future.

Contact Us

Sheela AK
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/